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OBJECTIVES The purpose of this study was to assess the follow-up of patients with vaccinia-associated
myocarditis.
BACKGROUND With the threat of biological warfare, the U.S. Department of Defense resumed a program
for widespread smallpox vaccinations on December 13, 2002. One-year afterwards, there has
been a significant increase in the occurrence of myocarditis and pericarditis among those
vaccinated.
METHODS Cases were identified through sentinel reporting to military headquarters, systematic
surveillance, and spontaneous reports.
RESULTS A total of 540,824 military personnel were vaccinated with a New York City Board of Health
strain of vaccinia from December 2002 through December 2003. Of these, 67 developed
myopericarditis at 10.4  3.6 days after vaccination. The ST-segment elevation was noted in
57%, mean troponin on admission was 11.3 22.7 ng/dl, and peak cardiac enzymes were
noted within 8 h of presentation. On follow-up of 64 patients (96%) at a mean of 32  16
weeks, all patients had objective normalization of echocardiography, electrocardiography,
laboratory testing, graded exercise testing, and functional status; 8 (13%) reported atypical,
non-limiting persistent chest discomfort.
CONCLUSIONS Post-vaccinial myopericarditis should be considered in patients with chest pain within 30 days
after smallpox vaccination. Normalization of echocardiography, electrocardiography, and
treadmill testing is expected, and nearly all patients have resolution of chest pain on
follow-up. (J Am Coll Cardiol 2004;44:201–5) © 2004 by the American College of
Cardiology Foundations
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Che current U.S. Department of Defense (DoD) Smallpox
accination Program began on December 13, 2002, to
ounter the potential release of variola virus as an act of
errorism against U.S. military forces (1). Through April
004, the DoD has immunized over 615,000 personnel.
his represents the largest smallpox vaccination program
ince the eradication of smallpox in 1977 (2).
Although sporadic cases of myocarditis and pericarditis
ere reported with various strains of smallpox vaccine (3),
hese complications were unexpected with the current strain
f smallpox vaccine (New York City Board of Health
NYCBOH] strain) (4,5). The DoD clinicians detected a
From the U.S. Army Medical Command, *Brooke Army Medical Center, Fort
am Houston, Texas, and ‡Walter Reed Army Medical Center, Washington, DC;
accine Healthcare Center, †Naval Medical Center, Portsmouth, Virginia, and
*Washington, DC; §Army Medical Surveillance Activity, Washington, DC; Wil-
ord Hall Medical Center, Lackland Air Force Base, San Antonio, Texas; ¶Mayo
linic and Foundation, Rochester, Minnesota; #Centers for Disease Control and
revention, Atlanta, Georgia; and ††Office of the Assistant Secretary of Defense for
ealth Affairs and the ‡‡Military Vaccine Agency, U.S. Army Medical Command,
alls Church, Virginia. The views expressed in this study are those of the authors and
o not reflect the official policy or position of the U.S. government.
Manuscript received April 10, 2004; revised manuscript received April 20, 2004,bccepted May 4, 2004.tatistically elevated rate of myopericarditis above back-
round levels after smallpox vaccination (6,7). Between
ecember 2002 and December 2003, a total of 67 cases of
yopericarditis within 30 days after smallpox vaccination
ere identified among 540,824 vaccinees, based on a con-
ensus case definition (8).
ETHODS
urveillance for adverse events. The DoD Smallpox Vac-
ination Program emphasized post-vaccination adverse-
vent surveillance and patient education (1). Vaccinees
eceived full-strength concentration of smallpox vaccine
Dryvax, Wyeth Laboratories, Marietta, Pennsylvania),
hich contains the NYCBOH strain. Cases of myopericar-
itis were detected through surveillance methods previously
escribed (1,6). Guidelines were published alerting provid-
rs to the diagnostic criteria and encouraging them to report
ases using the Vaccine Adverse Event Reporting System.
he Vaccine Healthcare Centers Network collected patient
ata in a centralized registry.
ase identification. Cases were classified by a committee
ased upon surveillance case definitions for myocarditis and
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Postvaccinial Myocarditis: Presentation and Follow-Up July 7, 2004:201–5ericarditis (6,8). These definitions included “possible or sus-
ect myopericarditis” if patients had symptoms without objec-
ive pathologic manifestation of disease; “probable myocarditis”
f elevated cardiac enzymes were present, and “probable peri-
arditis” if patients had pathologic electrocardiographic (ECG)
hanges or pathologic pericardial effusion. “Confirmed” cases
ad histopathologic evidence of myocardial inflammation (8).
emporal association was defined as occurrence of symptoms
r diagnosis within 30 days of vaccination. Suspect cases were
xcluded from this analysis.
tatistical analysis. Statistical analysis was performed us-
ng JMP Professional Software 5.0.1 (SAS Institute Inc.,
ary, North Carolina). The Student t test was used to
ompare continuous variables. Yate’s corrected chi-square
est was used for categorical variables, with the Fisher exact
est used if cells had 5 responses in any one group. The p
alues were considered statistically significant when 0.05.
linical follow-up protocol. Standardized guidelines for
atient follow-up developed by DoD and first distributed on
une 9, 2003, advocated repeat clinical evaluation and
aboratory investigation including ECG, echocardiography,
nd functional stress testing at 6 to 12 weeks, when feasible
9). Patients with persistent symptoms were transferred at
he discretion of the clinician to regional military tertiary-
are hospitals.
ESULTS
emographics. The clinical characteristics of all 67 cases
f probable or confirmed post-vaccinial myopericarditis
eported among 540,824 total vaccinees are summarized in
able 1. The cases were predominantly male (n  66;
8.5%) and Caucasian (n  60; 89.6%).
Abbreviations and Acronyms
CK  creatine kinase
DoD  Department of Defense
ECG  electrocardiogram
MI  myocardial infarction
NYCBOH  New York City Board of Health
able 1. Demographics of Patients With Vaccinia-Associated
yopericarditis
Total Cases (n  67)
ge (yrs) 26.6  5.2 (18.8–43.0)
thnicity
Caucasian 60 (89.5)
African-American 4 (6.0)
Hispanic 2 (3.0)
Asian 1 (1.5)
ender
Male 66 (98.5)
Female 1 (1.5)
ays from vaccination to evaluation 10.4  3.6 (3–25)
eeks to follow-up 31.0  16.0 (1.6–58.1)
ontinuous variables are expressed as mean  SD (range). Categorical variables are
Expressed as raw data (percent of column total).linical presentation. All 67 cases presented initially with
hest pain or substernal pressure. Prodromal symptoms were
ocumented in 61 (91.1%) patients. Fever and chills were
oted in 35 (57.4%) patients; myalgias and/or arthralgias in
9 (31.2%) patients; and headache, non-specific viral syn-
rome, and fatigue reported in 26 (34.4%) patients. Nine
atients (14.7%) had no prodromal syndrome until chest
ain prompted medical evaluation.
Follow-up data became available on 64 (96%) patients at
mean of 32  16 weeks after presentation (until April 15,
004). Two of the other three patients self-reported as
ealthy but voluntarily separated from military service and
eclined to return for follow-up care; one patient died
uring hospitalization. Eight (13%) patients reported con-
inued atypical, non-specific chest discomfort, three (5%)
atients reported continued fatigue, and two (3%) reported
omplaints of headache. Except for the single fatality, in no
ase did symptoms disqualify patients from continued active
ilitary service.
The single fatality occurred 33 days after multiple vacci-
ations. The case was reviewed by two independent groups
f physicians, who judged the fatality as possibly associated
ith vaccination, although a definitive link to smallpox or
ny other specific vaccine could not be established (1,10–
3).
ardiac catheterization. Catheterization with coronary
ngiography was performed in 29 (43.2%) patients, with
one revealing flow-limiting coronary atherosclerotic le-
ions. The mean left ventricular end-diastolic pressure was
6  5 mm Hg (range 9 to 22 mm Hg).
lectrocardiography. Electrocardiography during initial
resentation was reviewed in 61 (91.0%) patients. Six other
atients did not have available ECG data, because initial
reatment was in remote locations. Sinus rhythm was
resent in all 61 ECGs reviewed, and an identifiable
bnormality was evident in 46 (75.4%). The most common
bnormalities were ST-segment changes, evident in 40
65.6%) patients; 5 (8.2%) had normal variant early repo-
arization as defined by Wang et al. (14), and T-wave
bnormalities were noted in 11 (18.0%) (Table 2). Two
able 2. Vital Signs and Electrocardiographic Parameters in
atients With Vaccinia-Associated Myocarditis
Presentation
(n  61)
Follow-Up
(n  44)
ystolic blood pressure, mmHg 114  11 121  13
iastolic blood pressure, mmHg 73  8 73  10
eart rate, beats/min 74  17 74  14
inus rhythm 61 (100%) 41 (100%)
R interval, ms 150  22 150  24
RS duration, ms 90  9 91  9
T interval, ms 373  43 378  27
athologic ST-segment elevation* 35 (57.4%) 0 (0.0%)
 0.05 for all comparisons. Continuous variables are expressed as mean  SD.
ategorical variables are expressed as raw data (percent of column total). *Pathologic
lectrocardiogram changes were defined as a new finding of ST-segment elevation1
m (0.1 mV) elevation in two or more contiguous leads.CGs showed incomplete right bundle branch block, and
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July 7, 2004:201–5 Postvaccinial Myocarditis: Presentation and Follow-Upwo ECGs showed PR depression. Focal ST-segment
levation was more common than diffuse change, with
nferior and inferolateral ST-segment elevation accounting
or 45% of pathologic changes.
Forty-four of the 61 patients were matched with a
ollow-up ECG (72%). These ECGs, obtained from 20 to
62 days (median 108 days) from initial presentation,
evealed normalization of pathologic ST-segment elevation
nd T-wave inversions in all patients; non-specific changes
rom initial presentation remained evident in only one
atient.
aboratory studies. Cardiac enzymes were elevated in 60
f 61 (98.4%) patients evaluated with this assay. The three
ases with troponin-T elevation were excluded from further
nalysis. Original quantitative laboratory reports (excluding
ualitative reports of troponin “positive” or “negative”) were
vailable for 54 of 60 cases (81.6%). The mean peak creatine
inase (CK) was 510 IU/l (range 58 to 1,425 IU/l), and
ean peak troponin-I was 14.1 ng/ml (range 0.12 to 139.10
g/ml). Peak CK and troponin-I were collected at a median
able 3. Echocardiography and Vaccinia-Associated
yopericarditis
Presentation
(n  57)
Follow-Up
(n  40)
V ejection fraction 55  8 60  3*
30% to 40% 5 (9.0) 0 (0.0)
40% to 55% 13 (23.0) 1 (2.5)
55% 39 (68.0) 39 (97.5)
ericardial effusion 7 (12.3) 0 (0.0)†
egional wall motion abnormality 8 (14.0) 0 (0.0)*
VIDed, cm 5.0  0.6 4.9  0.5
VIDes, cm 3.4  0.6 3.2  0.5
p  0.05, †p  0.04 by one-tailed Fisher exact test.
ed  end-diastolic; es  end-systolic; ID  internal dimension; IVS  interventricular
eptum; LV  left ventricle.
Table 4. Acute Manifestations in Vaccinia-Ass
Recovery Status
Age, yrs
Time from vaccination to evaluation, days
Time to follow-up, weeks
Echocardiography
Abnormal at presentation
Ejection fraction at presentation, %
Ejection fraction on follow-up, %
Abnormal ECG on presentation
Cardiac isoenzymes, mean  SD
Creatine kinase (IU/l), peak
CK-MB (ng/dl), peak
Troponin-I (ng/dl), peak
Treadmill testing
Maximum heart rate, beats/min
Percent age-predicted, %
Duration, min
Metabolic equivalents
p  0.049, otherwise, not statistically significant. Continuou
expressed as raw data (percent of column total).CK  creatine kinase; ECG  electrocardiogram.f 1.5 and 6.9 h, respectively, from presentation with chest
ain.
In four cases where myocardial tissue was obtained, there
as no evidence of active vaccinia infection by culture or
eoxyribonucleic polymerase chain reaction assays. In the
hree cases of right ventricular biopsy, inflammatory changes
ere found: one with no clear cellular infiltrate, one with
ild lymphocytic infiltrate, and a third with eosinophilic
nfiltrate predominance (15). In the fatal case, in which
rolonged pulmonary illness preceded cardiac enzyme ele-
ation, postmortem examination revealed epicardial inflam-
ation with eosinophilic predominance, but without his-
opathologic evidence of myocarditis.
chocardiography. Of 67 patients, 57 (85.1%) were eval-
ated with echocardiography during acute illness (Table 3).
t follow-up echocardiography (n  40), at 11 to 362 days
median 102 days) after diagnosis, the mean ejection frac-
ion was 61  4% (range 54% to 75%), with no residual
vidence of ventricular dilation, diastolic dysfunction, re-
ional wall motion abnormality, or pericardial effusion.
unctional assessment. Graded exercise testing was per-
ormed using the Bruce protocol in 41 patients at 18 to 362
ays (median 103 days) from the time of diagnosis. The
ean exercise duration was 12.2  1.8 min (range 9.0 to
5.5 min). The mean maximum heart rate achieved was
6.0  5.6% age predicted with a rate-pressure product of
0,853  5,203. Testing precipitated no cardiac symptoms
r ECG abnormalities.
ersistently symptomatic patients. Unlike the objective
ormalization of cardiac findings at follow-up, 14% of
atients reported continued subjective symptoms (Table 4).
o significant difference occurred in follow-up ejection
raction, functional status, or resting ECG abnormalities
mong these patients, although those with persistent symp-
ed Myopericarditis Patients, Stratified by
ull Recovery
(n  50)
Continued Symptoms
(n  14)
27.1  5.6 25.1  3.6
10.4  3.7 10.0  2.0
30.0  15.6 34.6  15.6
5/43 (34.9%) 8/12 (66.7%)
57  8 51  8*
61  4 60  1
8/46 (61.0%) 7/11 (63.6%)
529  360 484  303
36.0  21.6 31.1  21.7
13.6  24.3 17.0  28.8
183  10 176  9
95.2  4.6 93.6  10.3
12.4  1.8 11.3  1.5
15.0  2.2 13.6  0.5
bles are expressed as mean  SD. Categorical variables areociat
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Postvaccinial Myocarditis: Presentation and Follow-Up July 7, 2004:201–5oms may have had more myocardial depression at
resentation.
ollow-up on patients with depressed ejection fractions.
omparing those 18 patients who presented with a de-
ressed ejection fraction (mean 47  6%) to the 39 patients
ith normal function (61  4%; p  0.01); there was no
tatistically significant difference in peak troponin-I (17.7
3.1 ng/ml vs. 12.3  25.9 ng/ml; p  0.49) or peak CK
566  353 IU/l vs. 478  343 IU/l; p  0.40). At
ollow-up, there was no difference in ejection fraction (59
% vs. 60  3%; p  0.06), or functional capacity (11.6 
.5 min vs. 12.7  1.8 min; p  0.41). No patient on
ollow-up had an ejection fraction 54%.
ISCUSSION
linical myocarditis or pericarditis is an expected rare
omplication of smallpox vaccination with the NYCBOH
train of vaccinia. All evaluated patients had objective
ormalization of cardiac function at follow-up. Approxi-
ately 20% reported persistent symptoms despite normal
esting. Normalization of echocardiography, ECG, and
unctional status can be expected, even in those with a
epressed ejection fraction at presentation.
Pericarditis and myocarditis have been reported after
ther vaccinations, but they are extremely rare events
elative to the millions of individuals immunized; most case
eports described self-limited and benign conditions (6).
revious prospective studies identified ECG changes that
ay have been myocarditis or pericarditis in 1% to 3% of
eople who received a European strain of vaccinia (3,5).
ardiac involvement has similarly been associated with
aturally occurring outbreaks of smallpox in the 1960s
1,6,7).
Viral myocarditis can mimic acute myocardial infarction
MI) clinically, electrocardiographically, and biochemically
s suggested by the high rate of diagnostic coronary angio-
rams in our young cohort (16,17). Coronary events, in-
luding angina and MI, have not been causally associated
ith smallpox vaccination (18,19).
Myocarditis can occur after viral, rickettsial, bacterial, and
arasitic disease (20). Whether the underlying myocardial
ysfunction in vaccinia-associated myopericarditis is a result
f infectious, toxic, or immunologically mediated myocar-
ial damage is unclear. In our four biopsied cases, active
accinia infection of the heart was excluded. This suggests
hat vaccinia-associated myopericarditis is immunologically
ediated, rather than a result of viral infection of the
yocardium. Independent of pathogenesis, the underlying
esult involves both patchy or diffuse myocytolysis and
ntense infiltration with inflammatory cellular products
15,20). If the pathogenesis represents eosinophilic injury
ediated by autoimmune phenomena, corticosteroids may
e efficacious in inflammation, although immunosuppres-
ive therapy is generally considered ineffective in the tradi-
ional models of viral-induced myocarditis (21,22).The strength of this study lies in the large number of
enerally healthy people vaccinated and the comprehensive
ature of adverse event reporting after smallpox vaccination,
oth of which contribute to study power. This study does
ot address the occurrence of subclinical myopericarditis.
urther investigation is ongoing to better define potential
isk factors for post-vaccinial myopericarditis.
Finally, post-vaccinial myopericarditis should be consid-
red in the differential diagnosis of patients who develop
hest pain within 30 days after smallpox vaccination, which
an be expected to be self-limited.
cknowledgments
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